# EDGAR Filing Document

**Accession Number:** 0001256230
**File Stem:** 0001256230-25-000007
**Filing Date:** 2025-11
**Character Count:** 7179
**Document Hash:** 227147827e02fb2fe51232af33e7c07e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001256230-25-000007.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001256230-25-000007

**CONFORMED SUBMISSION TYPE**: 4/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251111

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BROSHY ERAN
- **CENTRAL INDEX KEY:** 0001256230

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36033
- **FILM NUMBER:** 251480783

**MAIL ADDRESS:**
- **STREET 1:** C/O VENTIV HEALTH
- **STREET 2:** 200 COTTONTAIL LN. VANTAGE COURT N.
- **CITY:** SOMERSET
- **STATE:** NJ
- **ZIP:** 08873
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Theravance Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001583107
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** UGLAND HOUSE, SOUTH CHURCH STREET
- **CITY:** GEORGE TOWN, GRAND CAYMAN
- **STATE:** CA
- **ZIP:** KY1-1104
- **BUSINESS PHONE:** 650-808-6000

**MAIL ADDRESS:**
- **STREET 1:** UGLAND HOUSE, SOUTH CHURCH STREET
- **CITY:** GEORGE TOWN, GRAND CAYMAN
- **STATE:** CA
- **ZIP:** KY1-1104

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BROSHY ERAN<br><sub>(Last) (First) (Middle)</sub><br>C/O THERAVANCE BIOPHARMA US, LLC<br>901 GATEWAY BLVD<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Theravance Biopharma, Inc. [ TBPH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2025-11-11 |  | S |  | 15500 | D | 18.50<sup>(1)</sup> | 75704 | D |  |
| Ordinary Shares | 2025-11-11 |  | S |  | 15500 | D | 17<sup>(1)</sup> | 60204 | D |  |
| Ordinary Shares | 2025-11-11 |  | S |  | 14000 | D | 18.50<sup>(2)</sup> | 60204 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (Right to Buy) | $10.15 | 2025-11-11 |  | M |  | 14000 |  | <sup>(3)</sup> | 2032-04-25 | Ordinary Shares | 14000 | $10.15 | 107878 | D |  |

---

### Footnotes:

(1) The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

(2) The reporting person exercised stock options to acquire 14,000 Ordinary Shares and sold all such shares on the same day in a broker-assisted transaction. No shares were withheld for taxes. The transactions reported on this Form 4 were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

(3) This option was fully vested and exercisable (having vested as to 1/12th of the shares subject to the option upon completion of each continuous month of service following the original grant date and any remaining unvested shares vesting on the date of the next annual meeting of the company's shareholders provided continuous service through such date).

**Remarks:**
This Form 4/A is being filed to correct an administrative error in the number of Ordinary Shares reported as sold at $18.50 on November 11, 2025. The originally reported amount of 29,500 shares in Table I, Row 1 was incorrect; the correct amount is 15,500 shares. The number of Ordinary Shares beneficially owned following the transactions has been correspondingly adjusted in all three rows of Table I.

**Signature:** /s/ Brett Grimaud, Attorney-in-Fact  
**Date:** 2025-11-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**